← Issue №19/ week of Nov 8, 2026/ the whole section, in full

Esophagus/Reflux, in full.

All 3 Esophagus/Reflux papers in this issue, as full cards, ranked by clinical utility. The issue page carries the strongest few; this is the section, whole.

Sections this issue
Filter

All 3, in full

most clinically useful first · the 1 the issue led with is ruled in green
Esophagus/Reflux prospective cohort · n=136 · Nov 3, 2026 · Aliment Pharm Ther · IF 6.7

Clinical Trial: Capsule Sponge as a Non-Endoscopic Monitoring Tool in Eosinophilic Oesophagitis-A Prospective Real-World Multicentre Study.

New evidenceeosinophilic esophagitishealth services
Clinical takeawayIn adults with EoE without strictures, capsule sponge may reduce repeat endoscopies for monitoring; with sensitivity 76.3% (NPV 87.0%), a negative result does not exclude active disease.
What it foundCapsule sponge (CS) showed 76.3% sensitivity, 89.5% specificity, and 84.8% overall accuracy (Cohen's κ = 0.67) for monitoring EoE activity compared to endoscopic biopsies.
ContextProspective real-world study at three NHS sites (136 patients, 164 paired episodes); 92.7% swallowed the sponge with adequate sampling and no complications occurred.
Measured against the standard of care· ACG 2025 (Dellon et al., Am J Gastroenterol 120(1):31-59) / ASGE 2026 consensus Part 2 (Dellon et al., Gastrointest Endosc 103(3):396-417)

No single passage of this standard matched the paper closely enough to quote, so none is shown. The standard is cited above.

Our full summary of this standard

ACG 2025 (GRADE) is still the governing guideline. The ASGE 2026 consensus Part 2 (modified Delphi, 28 statements at ≥80% agreement; not GRADE) adds endoscopic and pediatric detail without contradicting it. DIAGNOSIS: symptoms of esophageal dysfunction plus ≥15 eos/hpf after excluding other causes of esophageal eosinophilia. A PPI trial is not a diagnostic criterion (PPI-REE abandoned). Do the initial diagnostic EGD off PPI, topical steroid and dietary therapy (ACG key concept; ASGE consensus, which gives no washout duration). Initial assessment is a standard EGD, not a less-invasive modality, so that full biopsies and dilation are possible (ASGE). Take ≥6 esophageal biopsies from ≥2 levels in anyone with symptoms or endoscopic findings consistent with EoE, targeting visible lesions. In CHILDREN with suspected EoE, also biopsy the stomach and duodenum (ASGE). Use EREFS at every endoscopy and report a quantified peak eosinophil count (ACG strong/low; ASGE). TREATMENT (ACG): swallowed topical steroids STRONG/moderate; high-dose PPI CONDITIONAL/low; empiric elimination diet CONDITIONAL/low. Choose a single initial therapy by shared decision-making. Fluticasone or budesonide are both reasonable. Adult doses: PPI double the reflux dose (e.g., omeprazole 20 mg BID or 40 mg daily); budesonide 2-4 mg/day (BOS 2 mg BID); fluticasone 1,760 mcg/day divided. Pediatric doses: PPI 2 mg/kg/day; budesonide 1-2 mg/day; fluticasone 110-880 mcg/day. Allergy testing is not used to direct diets. A 1FED/2FED step-up diet with a dietitian is acceptable, with endoscopic and biopsy confirmation after each reintroduced food. Dupilumab is CONDITIONAL for PPI-nonresponsive patients aged ≥12 (moderate) and for ages 1-11 at ≥15 kg (low). Weight-band dosing: 15-<30 kg 200 mg q2w; 30-<40 kg 300 mg q2w; ≥40 kg 300 mg weekly. Recommendations AGAINST: omalizumab, cromolyn, montelukast. No recommendation for cendakimab, benralizumab, lirentelimab, mepolizumab or reslizumab. DILATION: an adjunct to anti-inflammatory therapy for strictures causing dysphagia (ACG conditional/low). Start low and go slow; target ≥16 mm in adults and adolescents over ≥1 session. In children, ASGE supports dilation of symptomatic strictures or a narrow-caliber esophagus regardless of disease activity, using the same start-low/go-slow approach. MAINTENANCE: continue effective therapy (ACG STRONG despite low evidence) at the lowest effective dose. MONITORING: judge response on symptoms, endoscopy and histology together, never symptoms alone. Assess response endoscopically at 8-12 weeks after starting a PPI or topical steroid. For diet, ACG says 8-12 weeks and ASGE says 6-8 weeks. For dupilumab or biologics, assess at 12-24 weeks (ASGE: up to 24 weeks). Allow appropriate washout or timing after any treatment change before the follow-up EGD (ASGE). Take monitoring biopsies from the most severe-appearing lesions (rings, furrows, exudates) (ASGE). Monitoring biopsies may be limited to the esophagus when prior gastric and duodenal biopsies were normal and nothing new suggests other pathology (ASGE). The histologic response threshold of <15 eos/hpf is a 'may consider' target, read alongside endoscopic and symptom findings. Shorten follow-up after complications. Care gaps of ≥2 years are associated with fibrostenosis. PEDIATRIC (ACG): esophagram for children with dysphagia to assess fibrostenotic disease; feeding therapy and dietitian for feeding dysfunction; growth, development and nutrition are treatment goals.

ACG 2025 (Dellon et al., Am J Gastroenterol 120(1):31-59) / ASGE 2026 consensus Part 2 (Dellon et al., Gastrointest Endosc 103(3):396-417) · reviewed 2026-10-11 ↗
Kumar R … Morris DL · Alimentary Pharmacology & Therapeutics · IF 6.7 · PubMed ↗Permalink
Esophagus/Reflux retrospective · n=91 · Nov 2, 2026 · J Gastroenterology · IF 5.7

Salvage esophagectomy versus photodynamic therapy for localized residual or recurrent esophageal squamous cell carcinoma after definitive chemoradiotherapy or radiotherapy: a single-center comparative study.

New evidenceesophageal cancer
Clinical takeawayConsider PDT as an organ-preserving salvage option for localized residual or recurrent ESCC after CRT/RT in patients unsuitable for surgery due to advanced age, comorbidities, or limited surgical tolerance.
What it foundPDT achieved initial local complete response in 74.1% of patients compared to 94.0% R0 resection with salvage esophagectomy, with no significant difference in OS (p = 0.597) or DSS (p = 0.670).
ContextPDT demonstrated a favorable safety profile and may offer an organ-preserving salvage treatment option for carefully selected patients with localized residual or recurrent ESCC after definitive CRT or RT, particularly those unsuitable for surgery because of advanced age, substantial comorbidities, or limited surgical tolerance. This study does not establish equivalence or non-inferiority between PDT and salvage esophagectomy.
No standard claimed for this paper

Every paper is compared to the standard governing its question. This one is not: either no standard in the corpus matches it, or the comparison did not hold up on review and was withdrawn rather than published unverified. Both are logged.

Ujiie N … Kamei T · Journal of Gastroenterology · IF 5.7 · PubMed ↗Permalink
Esophagus/Reflux systematic review · n=43 · Nov 2, 2026 · Diseases of the Esophagus · IF 2.5

Leptomeningeal carcinomatosis arising from esophageal cancer: a systematic review of the literature.

New evidenceesophageal cancersystematic reviewepidemiologybiomarker
Clinical takeawayConsider individualized CNS-directed therapy (radiotherapy or intrathecal therapy) in selected patients with leptomeningeal disease from esophageal cancer, as rare long-term survival is reported. Prioritize early recognition and palliative care given the poor prognosis.
What it foundMedian survival in leptomeningeal carcinomatosis (LMC) from esophageal cancer is 1.1 months, with 3 patients achieving 12, 14, and 19 months survival after individualized CNS-directed therapy.
ContextConfirms the rarity, heterogeneity of presentation, and aggressiveness of LMC from esophageal cancer, previously only described in case reports and small series. Highlights the potential benefit of individualized CNS-directed therapy in a subset of patients.
No standard claimed for this paper

Every paper is compared to the standard governing its question. This one is not: either no standard in the corpus matches it, or the comparison did not hold up on review and was withdrawn rather than published unverified. Both are logged.

Mylonakis A … Schizas D · Diseases of the Esophagus : Official Journal of the International Society for Diseases of the Esophagus · IF 2.5 · PubMed ↗Permalink
← Back to issue №19 Every section of this issue is one click away, at the top of this page. Follow Esophagus/Reflux by RSS